ftc pharmacy benefit managers

Pharmacy benefit managers inflated drug prices by $7.3B

FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

Campus Safety Magazine · 1d

FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging

FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging, PBMs, UnitedHealth OptumRx, CVS Caremark Rx, Express Scripts

CNN on MSN · 2d

FTC finds middlemen inflate specialty generic drug prices by billions of dollars

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs between 2017 and 2022,

MedCity News1d

Healthcare Leaders Support FTC’s Second Report on PBMs, While PBMs Criticize Findings

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

1don MSN

UnitedHealth Charged Cancer Patients 5000%, Bombshell FTC Report Claims

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds or thousands ...

policymed.com2d

Second Federal Trade Commission Report on Pharmacy Benefit Managers (PBM’s) Focuses on Specialty Generics

The Federal Trade Commission (FTC) released its second interim staff report “Specialty Generic Drugs a Growing Profit Center ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Pharmacy benefit managers inflated drug prices by $7.3B

Trending now

Related topics